遺傳性血管水腫 (Chinese Wikipedia)

Analysis of information sources in references of the Wikipedia article "遺傳性血管水腫" in Chinese language version.

refsWebsite

Global rank Chinese rank

21web.archive.org

1^st place

9nih.gov

4^th place

5^th place

7doi.org

2^nd place

23^rd place

2fda.gov

447^th place

581^st place

1orpha.net

3,537^th place

low place

1rarediseases.org

5,181^st place

5,627^th place

1books.google.com

3^rd place

8^th place

1bravecommunity.com

low place

1caep.ca

low place

1haecanada.org

low place

1pia.org.uk

low place

1haeuk.org

low place

1omim.org

4,380^th place

low place

1drugs.com

399^th place

208^th place

1medscape.com

719^th place

889^th place

1takeda.com

low place

1worldcat.org

5^th place

12^th place

1haei.org

low place

1nytimes.com

7^th place

31^st place

1pharming.com

low place

1jerini.com

low place

1reuters.com

49^th place

81^st place

books.google.com

Levin, Alex V.; Enzenauer, Robert W. The Eye in Pediatric Systemic Disease. Springer. 2017: 71. ISBN 9783319183893. （原始内容存档于2017-09-10）（英语）.

bravecommunity.com

Archived copy. [2014-05-05]. （原始内容存档于2014-05-06）.

caep.ca

Archived copy (PDF). [2014-11-03]. （原始内容 (PDF)存档于2014-11-03）.

doi.org

Angioedema without urticaria: a large clinical survey. CMAJ. October 2006, 175 (9): 1065–70. PMC 1609157 . PMID 17060655. doi:10.1503/cmaj.060535.
C1 inhibitor deficiency: consensus document (PDF). Clinical and Experimental Immunology. March 2005, 139 (3): 379–94. PMC 1809312 . PMID 15730382. doi:10.1111/j.1365-2249.2005.02726.x. （原始内容 (PDF)存档于2009-04-20）.
Pathways of bradykinin degradation in blood and plasma of normotensive and hypertensive rats. Am. J. Physiol. Heart Circ. Physiol. May 2001, 280 (5): H2182–8. PMID 11299220. doi:10.1152/ajpheart.2001.280.5.H2182.
Inactivation of bradykinin by angiotensin-converting enzyme and by carboxypeptidase N in human plasma. Am. J. Physiol. Heart Circ. Physiol. April 2000, 278 (4): H1069–74. PMID 10749699. doi:10.1152/ajpheart.2000.278.4.H1069.
Varga, Lilian; Farkas, Henriette. Treatment of type I and II hereditary angioedema with Rhucin®, a recombinant human C1 inhibitor. Expert Review of Clinical Immunology. 2008-11-01, 4 (6): 653–661. ISSN 1744-666X. PMID 20477114. doi:10.1586/1744666X.4.6.653.
Lehmann A. Ecallantide (DX-88), a plasma kallikrein inhibitor for the treatment of hereditary angioedema and the prevention of blood loss in on-pump cardiothoracic surgery. Expert Opin Biol Ther. August 2008, 8 (8): 1187–99. PMID 18613770. doi:10.1517/14712598.8.8.1187.
Bernstein JA. Hereditary angioedema: a current state-of-the-art review, VIII: current status of emerging therapies. Ann. Allergy Asthma Immunol. January 2008, 100 (1 Suppl 2): S41–6. PMID 18220151. doi:10.1016/S1081-1206(10)60585-6.

drugs.com

存档副本. [2021-08-03]. （原始内容存档于2018-08-25）.

fda.gov

Drug Trials Snapshot: Orladeyo. U.S. Food and Drug Administration. 3 December 2020 [25 December 2020]. （原始内容存档于2021-10-24）. 本文含有此來源中屬於公有领域的内容。

accessdata.fda.gov

Orladeyo: FDA-Approved Drugs. U.S. Food and Drug Administration (FDA). [25 December 2020]. （原始内容存档于2022-02-27）.

haecanada.org

Diagnostic Algorithm. HAE Canada. [2014-11-03]. （原始内容存档于2014-11-03）.

haei.org

HAEi website. [2017-09-10]. （原始内容存档于2012-10-22）.

haeuk.org

More Information. HAE UK. （原始内容存档于2014-04-22）.

jerini.com

Jerini AG. Jerini Receives European Commission Approval for Firazyr (Icatibant) in the Treatment of HAE - Press release. 2008-07-15 [2008-07-28]. （原始内容存档于2018-09-29）.

medscape.com

存档副本. [2021-08-03]. （原始内容存档于2018-08-25）.

nih.gov

ncbi.nlm.nih.gov

Angioedema without urticaria: a large clinical survey. CMAJ. October 2006, 175 (9): 1065–70. PMC 1609157 . PMID 17060655. doi:10.1503/cmaj.060535.
C1 inhibitor deficiency: consensus document (PDF). Clinical and Experimental Immunology. March 2005, 139 (3): 379–94. PMC 1809312 . PMID 15730382. doi:10.1111/j.1365-2249.2005.02726.x. （原始内容 (PDF)存档于2009-04-20）.
Pathways of bradykinin degradation in blood and plasma of normotensive and hypertensive rats. Am. J. Physiol. Heart Circ. Physiol. May 2001, 280 (5): H2182–8. PMID 11299220. doi:10.1152/ajpheart.2001.280.5.H2182.
Inactivation of bradykinin by angiotensin-converting enzyme and by carboxypeptidase N in human plasma. Am. J. Physiol. Heart Circ. Physiol. April 2000, 278 (4): H1069–74. PMID 10749699. doi:10.1152/ajpheart.2000.278.4.H1069.
Varga, Lilian; Farkas, Henriette. Treatment of type I and II hereditary angioedema with Rhucin®, a recombinant human C1 inhibitor. Expert Review of Clinical Immunology. 2008-11-01, 4 (6): 653–661. ISSN 1744-666X. PMID 20477114. doi:10.1586/1744666X.4.6.653.
Lehmann A. Ecallantide (DX-88), a plasma kallikrein inhibitor for the treatment of hereditary angioedema and the prevention of blood loss in on-pump cardiothoracic surgery. Expert Opin Biol Ther. August 2008, 8 (8): 1187–99. PMID 18613770. doi:10.1517/14712598.8.8.1187.
Bernstein JA. Hereditary angioedema: a current state-of-the-art review, VIII: current status of emerging therapies. Ann. Allergy Asthma Immunol. January 2008, 100 (1 Suppl 2): S41–6. PMID 18220151. doi:10.1016/S1081-1206(10)60585-6.

ghr.nlm.nih.gov

Reference, Genetics Home. hereditary angioedema. Genetics Home Reference. 5 July 2017 [10 July 2017]. （原始内容存档于10 July 2017）（英语）.

rarediseases.info.nih.gov

Hereditary angioedema. GARD. 2017 [10 July 2017]. （原始内容存档于4 July 2017）（英语）.

nytimes.com

The New York Times Magazine. [2020-12-29]. （原始内容存档于2022-03-27）.

omim.org

OMIM Entry - # 610618 - ANGIOEDEMA, HEREDITARY, TYPE III; HAE3. www.omim.org. [2018-12-21]. （原始内容存档于2019-03-27）.

orpha.net

Orphanet: Hereditary angioedema. www.orpha.net. August 2011 [10 July 2017]. （原始内容存档于9 October 2015）（英语）.

pharming.com

Pharming: Pharming Receives Positive Opinion From European Medicines Agency On Rhucin Product name in Europe changed to Ruconest （页面存档备份，存于互联网档案馆）

pia.org.uk

C1 inhibitor deficiency: consensus document (PDF). Clinical and Experimental Immunology. March 2005, 139 (3): 379–94. PMC 1809312 . PMID 15730382. doi:10.1111/j.1365-2249.2005.02726.x. （原始内容 (PDF)存档于2009-04-20）.

rarediseases.org

Hereditary Angioedema - NORD (National Organization for Rare Disorders). NORD (National Organization for Rare Disorders). 2008 [10 July 2017]. （原始内容存档于14 July 2017）.

reuters.com

Reuters: UPDATE 1-US clears Lev Pharma drug for rare swelling disease 互联网档案馆的存檔，存档日期2009-09-09.

takeda.com

FDA Approves sBLA for Takeda’s TAKHZYRO for HAE Attacks in 2y/o and up. www.takeda.com. [2023-02-06]. （原始内容存档于2023-02-06）（英语）.

web.archive.org

Reference, Genetics Home. hereditary angioedema. Genetics Home Reference. 5 July 2017 [10 July 2017]. （原始内容存档于10 July 2017）（英语）.
Hereditary angioedema. GARD. 2017 [10 July 2017]. （原始内容存档于4 July 2017）（英语）.
Orphanet: Hereditary angioedema. www.orpha.net. August 2011 [10 July 2017]. （原始内容存档于9 October 2015）（英语）.
Hereditary Angioedema - NORD (National Organization for Rare Disorders). NORD (National Organization for Rare Disorders). 2008 [10 July 2017]. （原始内容存档于14 July 2017）.
Levin, Alex V.; Enzenauer, Robert W. The Eye in Pediatric Systemic Disease. Springer. 2017: 71. ISBN 9783319183893. （原始内容存档于2017-09-10）（英语）.
Archived copy. [2014-05-05]. （原始内容存档于2014-05-06）.
Archived copy (PDF). [2014-11-03]. （原始内容 (PDF)存档于2014-11-03）.
Diagnostic Algorithm. HAE Canada. [2014-11-03]. （原始内容存档于2014-11-03）.
C1 inhibitor deficiency: consensus document (PDF). Clinical and Experimental Immunology. March 2005, 139 (3): 379–94. PMC 1809312 . PMID 15730382. doi:10.1111/j.1365-2249.2005.02726.x. （原始内容 (PDF)存档于2009-04-20）.
More Information. HAE UK. （原始内容存档于2014-04-22）.
OMIM Entry - # 610618 - ANGIOEDEMA, HEREDITARY, TYPE III; HAE3. www.omim.org. [2018-12-21]. （原始内容存档于2019-03-27）.
存档副本. [2021-08-03]. （原始内容存档于2018-08-25）.
存档副本. [2021-08-03]. （原始内容存档于2018-08-25）.
Drug Trials Snapshot: Orladeyo. U.S. Food and Drug Administration. 3 December 2020 [25 December 2020]. （原始内容存档于2021-10-24）. 本文含有此來源中屬於公有领域的内容。
Orladeyo: FDA-Approved Drugs. U.S. Food and Drug Administration (FDA). [25 December 2020]. （原始内容存档于2022-02-27）.
FDA Approves sBLA for Takeda’s TAKHZYRO for HAE Attacks in 2y/o and up. www.takeda.com. [2023-02-06]. （原始内容存档于2023-02-06）（英语）.
HAEi website. [2017-09-10]. （原始内容存档于2012-10-22）.
The New York Times Magazine. [2020-12-29]. （原始内容存档于2022-03-27）.
Pharming: Pharming Receives Positive Opinion From European Medicines Agency On Rhucin Product name in Europe changed to Ruconest （页面存档备份，存于互联网档案馆）
Jerini AG. Jerini Receives European Commission Approval for Firazyr (Icatibant) in the Treatment of HAE - Press release. 2008-07-15 [2008-07-28]. （原始内容存档于2018-09-29）.
Reuters: UPDATE 1-US clears Lev Pharma drug for rare swelling disease 互联网档案馆的存檔，存档日期2009-09-09.

worldcat.org

Varga, Lilian; Farkas, Henriette. Treatment of type I and II hereditary angioedema with Rhucin®, a recombinant human C1 inhibitor. Expert Review of Clinical Immunology. 2008-11-01, 4 (6): 653–661. ISSN 1744-666X. PMID 20477114. doi:10.1586/1744666X.4.6.653.